According to the National Venture Capital Association, venture capital investing in the biotechnology arena continue to be robust.

Biotechnology had $1.1 billion going into 99 deals in the third quarter, Heesen told BioWorld Today. VCs invested $1.2 billion in biotech in 124 deals in the second quarter, and in the first quarter, "the strongest quarter ever recorded for the amount of money" for biotech, VCs invested $1.5 billion in 106 deals, he added.

As before, there is however a reluctance from VCs to back early-stage ventures. Read the full report from BioWorld.